Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 54 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CF Pharma from Beaumont, company number BE0843643840, closed financial year 2025 with a result of € 31,984 after tax. For that financial year CF Pharma recorded a gross margin of € 89,505 and equity of € 78,607. Compared with financial year 2024, the result moved from € 24,104 to € 31,984. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.
€ 78,607
▲ 69% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 31,984
▲ 33% vs 2024
Profit after tax over the fiscal year.
€ 2,529
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 20,007.
Debts at end 2025
€ 349,383
▼ 9% vs 2024
€ 28,217 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.
€ 2,004
▲ 148% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,415
▲ 5% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 16,512 | € 16,326 | € 84,231 | € 89,505 | ▲ 6% |
| Profit after taxes | € 11,411 | € -2,827 | € 24,104 | € 31,984 | ▲ 33% |
| Equity | € 25,346 | € 22,519 | € 46,623 | € 78,607 | ▲ 69% |
| Total debts | € 64,587 | € 151,323 | € 476,803 | € 390,707 | ▼ 18% |
| Cash | - | € 1 | - | € 2,529 | |
| Land & buildings | € 1,229 | € 115,254 | € 439,280 | € 429,668 | ▼ 2% |
| Retained profit | € -33,254 | € -36,081 | € -11,977 | € 20,007 | ▲ € 31,984 |
| Bank debt | € 59,159 | € 103,362 | € 383,697 | € 349,383 | ▼ 9% |
| Balance sheet total | € 89,933 | € 173,841 | € 523,426 | € 469,314 | ▼ 10% |
Key figures of CF Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CF Pharma?
What happened at CF Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 31,984 (▲ 33% vs 2024). Source: NBB ↗
- Frederic Chretien became a director. NBB
- New establishment in Thuin. KBO
- Start of the company according to the CBE. KBO
In short
From € 11,411 profit in 2022 to € 31,984 profit in 2025.
Paid € 24,067 in corporate taxes since 2022.
Best year ever: 2025, with € 31,984 profit.
Management
Behind CF Pharma is Frederic Chretien.
Directors
According to the 2025 annual accounts
Frederic Chretien
Manager
since 2018
Establishments
Establishment units
Physical locations of this company
Grand Place(BT) 23
6500 Beaumont
Rue des Fauldeurs 7
6530 Thuin
Active since 14 February 2012
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0843.643.840
- VAT number
- BE 0843.643.840
- Registered office
- Grand Place(BT) 23, 6500 Beaumont
- Names & denominations
- CF Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 February 2012
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels